Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 12/20 | 0.56 |
| ▸ | CRBN | Q96SW2 | 12/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29279158 | 0.94 | DDB1 (0.53) | DDB1CRBNHRH3PDE4BUSP30 | |
| SCHEMBL29279129 | 0.94 | DDB1 (0.53) | DDB1CRBNHRH3PDE4BUSP30 | |
| SCHEMBL29279138 | 0.94 | DDB1 (0.53) | DDB1CRBNHRH3PDE4BUSP30 | |
| SCHEMBL29976937 | 0.93 | DDB1 (0.52) | DDB1CRBNHRH3PDE4BKDM4E | |
| SCHEMBL23538562 | 0.92 | DDB1 (0.55) | DDB1CRBNHRH3PDE4BKDM4E | |
| SCHEMBL29946867 | 0.91 | DDB1 (0.54) | DDB1CRBNHRH3PDE4BKDM4E | |
| SCHEMBL31160654 | 0.89 | DDB1 (0.47) | DDB1CRBNUSP30 | |
| SCHEMBL30738778 | 0.88 | DDB1 (0.50) | DDB1CRBNHRH3KDM4E | |
| SCHEMBL27179051 | 0.88 | DDB1 (0.50) | DDB1CRBNHRH3KDM4E | |
| SCHEMBL30990766 | 0.87 | DDB1 (0.52) | DDB1CRBNPDE4BUSP30KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062426-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4673449-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | Differentiated Therapeutics Inc (US) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024182555-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062426-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | CCNA1, CCNE1, CCNA2 | DDB1 308/4885CRBN 429/4885HRH3 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.